These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 21224931)

  • 61. Ranolazine (Ranexa) in the treatment of chronic stable angina.
    Aslam S; Gray D
    Adv Ther; 2010 Apr; 27(4):193-201. PubMed ID: 20449698
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Perspective: does ranolazine have potential for the treatment of atrial fibrillation?
    Hancox JC; Doggrell SA
    Expert Opin Investig Drugs; 2010 Dec; 19(12):1465-74. PubMed ID: 21105855
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Ranolazine reduces atrial fibrillatory wave frequency.
    Black-Maier EW; Pokorney SD; Barnett AS; Liu P; Shrader P; Ng J; Goldberger JJ; Zareba W; Daubert JP; Grant AO; Piccini JP
    Europace; 2017 Jul; 19(7):1096-1100. PubMed ID: 27756767
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Advances in the management of stable angina.
    Trujillo TC
    J Manag Care Pharm; 2006 Oct; 12(8 Suppl):S10-6. PubMed ID: 23577423
    [TBL] [Abstract][Full Text] [Related]  

  • 65. New Anti-Anginal Drugs: Ranolazine.
    Cavallino C; Facchini M; Veia A; Bacchni S; Rosso R; Rognoni A; Rametta F; Lupi A; Bongo AS
    Cardiovasc Hematol Agents Med Chem; 2015; 13(1):14-20. PubMed ID: 25544118
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Evaluation of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina: results from the TERISA randomized clinical trial (Type 2 Diabetes Evaluation of Ranolazine in Subjects With Chronic Stable Angina).
    Kosiborod M; Arnold SV; Spertus JA; McGuire DK; Li Y; Yue P; Ben-Yehuda O; Katz A; Jones PG; Olmsted A; Belardinelli L; Chaitman BR
    J Am Coll Cardiol; 2013 May; 61(20):2038-45. PubMed ID: 23500237
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Anti-anginal and anti-ischemic effects of late sodium current inhibition.
    Wimmer NJ; Stone PH
    Cardiovasc Drugs Ther; 2013 Feb; 27(1):69-77. PubMed ID: 23247666
    [TBL] [Abstract][Full Text] [Related]  

  • 68. [Conservative therapy of patients with stable coronary heart disease].
    Custodis F; Laufs U
    Herz; 2012 Feb; 37(1):85-96. PubMed ID: 22331062
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Inhibition of sodium-dependent calcium overload to treat myocardial ischemia.
    Conti CR
    Clin Cardiol; 2006 Apr; 29(4):141-3. PubMed ID: 16649721
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Ranolazine: a potential new treatment for chronic stable angina.
    Anderson JR; Khou S; Nawarskas JJ
    Heart Dis; 2001; 3(4):263-9. PubMed ID: 11975803
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Does ranolazine have a place in the treatment of acute coronary syndromes?
    Newby LK; Peterson ED
    JAMA; 2007 Apr; 297(16):1823-5. PubMed ID: 17456825
    [No Abstract]   [Full Text] [Related]  

  • 72. Effects of ranolazine in symptomatic patients with stable coronary artery disease. A systematic review and meta-analysis.
    Savarese G; Rosano G; D'Amore C; Musella F; Della Ratta GL; Pellegrino AM; Formisano T; Vitagliano A; Cirillo A; Cice G; Fimiani L; del Guercio L; Trimarco B; Perrone-Filardi P
    Int J Cardiol; 2013 Nov; 169(4):262-70. PubMed ID: 24063912
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Use of ranolazine in the prevention and treatment of postoperative atrial fibrillation in patients undergoing cardiac surgery.
    Tsu LV; Lee S
    Ann Pharmacother; 2014 May; 48(5):633-7. PubMed ID: 24523397
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Effects of ranolazine on various outcomes in patients with stable angina: an updated meta-analysis.
    Manolis A; Kallistratos M; Poulimenos L; Zamfir T; Thomopoulos C
    Hellenic J Cardiol; 2023; 71():26-32. PubMed ID: 36481415
    [TBL] [Abstract][Full Text] [Related]  

  • 75. A focus on antiarrhythmic properties of ranolazine.
    Vizzardi E; D'Aloia A; Quinzani F; Bonadei I; Rovetta R; Bontempi L; Curnis A; Dei Cas L
    J Cardiovasc Pharmacol Ther; 2012 Dec; 17(4):353-6. PubMed ID: 22492919
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Efficacy and safety of a metabolic modulator drug in chronic stable angina: review of evidence from clinical trials.
    Chaitman BR
    J Cardiovasc Pharmacol Ther; 2004 Sep; 9 Suppl 1():S47-64. PubMed ID: 15378131
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Ranolazine. A metabolic modulator for the treatment of chronic stable angina.
    Anderson JR; Nawarskas JJ
    Cardiol Rev; 2005; 13(4):202-10. PubMed ID: 15949056
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Ranolazine: new paradigm for management of myocardial ischemia, myocardial dysfunction, and arrhythmias.
    Stone PH
    Cardiol Clin; 2008 Nov; 26(4):603-14. PubMed ID: 18929234
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Atrium-selective sodium channel block as a strategy for suppression of atrial fibrillation: differences in sodium channel inactivation between atria and ventricles and the role of ranolazine.
    Burashnikov A; Di Diego JM; Zygmunt AC; Belardinelli L; Antzelevitch C
    Circulation; 2007 Sep; 116(13):1449-57. PubMed ID: 17785620
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Ranolazine for the prevention or treatment of atrial fibrillation: a systematic review.
    Dagres N; Iliodromitis EK; Lekakis JP; Simitsis P; Karatzas D; Rallidis LS; Simeonidou E; Anastasiou-Nana M
    J Cardiovasc Med (Hagerstown); 2014 Mar; 15(3):254-9. PubMed ID: 24662415
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.